September 2007 Meeting Announcement, Delaware Valley Mass Spectrometry Discussion Group
- Topic: "Moving from HPLC/MS/MS Toward UHPLC/MS/MS in the Drug Discovery Setting
- Speaker: Dan Morgan (BMS)
- Date: Monday, September 10, 2007. 6:30 PM
- Time: Social Hour: 6:30 PM.
Talk: 7:30 PM.
Please RSVP to Christopher Petucci PETUCCC@wyeth.com by Thursday September 6th.
- Place: Department of Chemistry, Villanova University (Room 115, Mendel Hall)
Over the past decade, quantitative LC/MS/MS has become the standard analytical technique of choice in the drug discovery area. The need to provide quantitative data on potential drug candidates at low levels has necessitated the sensitivity and the specificity of tandem mass spectrometry. While the use of HPLC for the MS interface has been routinely accepted, decreasing individual sample analysis times, while maintaining data quality has always been desired. As a means of decreasing analysis times, researchers have tried using shorter columns, or eliminated analytical columns completely, to provide minimal separation and to decrease cycle times. The development of sub two micron particle columns and the development of chromatographic systems able to achieve higher operating pressures (UHPLC), has lead to a marked decrease in analysis times, while maintaining adequate resolution to support analysis.
This presentation will focus on the routine use of UHPLC systems coupled to tandem mass spectrometers for the analysis of analytes in biological matrices. Analysis times have been decreased to 1.1 minutes while sample resolution has been maintained. Data will be presented on the coupling of an Acquity UPLC system to an API4000 mass spectrometer along with the interfacing of an Agilent 1200 UHPLC system to an API4000. This presentation will focus on the ease of use for the various UHPLC systems and their advantages over a standard HPLC system. Considerations of increased sensitivity, linear range, effect of dwell time and the use of ESI and APCI will also be presented.
Dr. Morgan received a BS in Chemistry from Fairmont State College, Fairmont WV, in 1987. He received an M.S. and Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill in 1994 under the mentorship of Professor Emeritus Maurice Bursey. He worked for Glaxo, Glaxo Wellcome, and GlaxoSmithKline in the Research Triangle Park, NC for 14 years in the analytical and DMPK drug development and discovery areas. Dr. Morgan was the co-chair of the Triangle Area Mass Spectrometry Discussion group from 1997 until 2004.
Since 2004, Dr Morgan has lead the Bioanalytical Research Group at Bristol-Myers Squibb at the Wallingford CT site. The group is responsible for providing quantitative LC/MS/MS data for discovery programs. His research interests include: effects of ion suppression in ESI and coupling of supercritical fluid chromatography with mass spectrometry.
Please send any comments, corrections, or suggestions to
This page has been accessed
times since 9/15 /96 .
Last Updated 12/13/2006